Natalie Callander, MD, details findings from her study, evaluating the impact of quadruplet therapy on newly diagnosed patients with high-risk multiple myeloma.
Case: A 61-Year-Old Woman with Transplant-Preferred Newly Diagnosed Multiple Myeloma (NDMM)
Clinical Workup and Diagnosis:
Natalie Callander, MD: I was very happy to be the head of a group composed of GRIFFIN and MASTER investigators. We pooled our data to see the impact of these quadruplet regimens on the outcome of patients with high-risk cytogenetics. We found out that in both studies there were somewhat more high-risk patients in the MASTER trial because it was amended to enrich for those patients. In both studies, the high-risk patients—those who had 2 or more high-risk cytogenetic abnormalities—were benefiting but at a lower rate.
Initially, their MRD [minimal residual disease]–negativity rate was fine, but we got there. Over time, they had a deterioration. With a several-year follow-up, we were seeing that only 60% of patients in both studies were remaining MRD negative. Both were consistent in 2 different approaches with these quadruplet regimens, but they signal that we need to do more for patients with 2 or more cytogenic abnormalities, either in the induction part or more likely in the maintenance phase—perhaps the addition of longer therapy or more or novel drugs in that area.
Transcript edited for clarity.